[go: up one dir, main page]

AU2003224132A1 - Effective sirna knock-down constructs - Google Patents

Effective sirna knock-down constructs

Info

Publication number
AU2003224132A1
AU2003224132A1 AU2003224132A AU2003224132A AU2003224132A1 AU 2003224132 A1 AU2003224132 A1 AU 2003224132A1 AU 2003224132 A AU2003224132 A AU 2003224132A AU 2003224132 A AU2003224132 A AU 2003224132A AU 2003224132 A1 AU2003224132 A1 AU 2003224132A1
Authority
AU
Australia
Prior art keywords
effective sirna
sirna knock
down constructs
constructs
knock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003224132A
Other versions
AU2003224132A8 (en
Inventor
Gerardus Johannes Franciscus Arts
Carolina Johanna Leonarda Bergs
Remko Johannes Clasen
Kristina Djokic
Sandra Griffioen
Mark Jacques Yvonne Lambrecht
Emir Mesic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos Genomics NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Publication of AU2003224132A8 publication Critical patent/AU2003224132A8/en
Publication of AU2003224132A1 publication Critical patent/AU2003224132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003224132A 2003-04-24 2003-04-24 Effective sirna knock-down constructs Abandoned AU2003224132A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/004362 WO2004094636A1 (en) 2003-04-24 2003-04-24 Effective sirna knock-down constructs

Publications (2)

Publication Number Publication Date
AU2003224132A8 AU2003224132A8 (en) 2004-11-19
AU2003224132A1 true AU2003224132A1 (en) 2004-11-19

Family

ID=33305624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003224132A Abandoned AU2003224132A1 (en) 2003-04-24 2003-04-24 Effective sirna knock-down constructs

Country Status (2)

Country Link
AU (1) AU2003224132A1 (en)
WO (1) WO2004094636A1 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
AU2003267347A1 (en) * 2003-09-10 2005-03-29 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
EP1709176A1 (en) * 2004-01-21 2006-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
WO2005097189A1 (en) 2004-04-09 2005-10-20 Genecare Research Institute Co., Ltd. Carcinoma cell-specific apoptosis inducing agent targeting gene relevant to chromosome stabilization
EP2267458A3 (en) 2004-04-20 2011-04-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
EP2214018B1 (en) 2004-04-27 2013-06-26 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP2270160A1 (en) 2004-06-14 2011-01-05 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
WO2005124342A2 (en) 2004-06-21 2005-12-29 Galapagos N.V. Methods and means for treatment of osteoarthritis
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
TWI386225B (en) * 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
WO2006108582A2 (en) * 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND USES FOR MODULATING EXPRESSION OF PTPRU
US8795976B2 (en) 2005-07-29 2014-08-05 Oncotherapy Science, Inc. Gene and polypeptide relating to breast cancer
KR20070101610A (en) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Method of overcoming cancer gene therapy and anticancer drug resistance using small interference NTA that suppresses expression of AN2 gene
JP5473594B2 (en) 2006-04-13 2014-04-16 アルコン リサーチ， リミテッド RNAi-mediated inhibition of histamine receptor H1-related conditions
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
EP2152878A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE (PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2008137776A2 (en) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
WO2008137771A2 (en) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2152875A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
EP2198021A4 (en) * 2007-08-24 2011-01-19 Oncotherapy Science Inc EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET THERAPY AND DIAGNOSTIC GENES OF LUNG CANCER
CA2705316A1 (en) * 2007-11-09 2009-05-14 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
WO2010004051A1 (en) * 2008-07-11 2010-01-14 Medizinische Universität Innsbruck Antagonists of nr2f6 for augmenting the immune response
ES2343292B1 (en) * 2008-07-24 2011-06-20 Universidad Complutense De Madrid SIRNA AND SHRNA FOR THE ELABORATION OF MEDICINES AGAINST THE ELEVATED PRESSURE INTRAOCULAR.
EP2352828B1 (en) 2008-09-11 2015-02-25 Galapagos N.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
WO2010094734A2 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398480A1 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
JP2012517821A (en) 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ Identification method and compound useful for diagnosis and treatment of diseases including inflammation
WO2010111468A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
US8663930B2 (en) 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
EP2236607A1 (en) * 2009-04-02 2010-10-06 Sanofi-Aventis Use of inhibitors of St3Gla6 activity for modulation of adipogenesis
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
CA2765509C (en) * 2009-06-16 2021-08-17 Joseph Collard Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011105901A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
CN103025873B (en) 2010-06-23 2018-05-08 库尔纳公司 Treatment of SCNA-associated diseases by inhibiting natural antisense transcripts of voltage-gated sodium channel alpha subunit (SCNA)
RU2014108824A (en) * 2011-09-14 2015-09-20 Ниппон Каяку Кабусики Кайся METHOD FOR INHIBITING A CELL GROWTH, A NUCLEIC ACID MOLECULE, MANIFESTING THE EFFECT OF RNA INTERFERENCE REGARDING THE GENE CODING THE NEK10 OPTION AND AN ANTITUM AN AGENT
BR112014009790A2 (en) 2011-10-25 2018-05-15 Isis Pharmaceuticals Inc compound for antisense modulation of gccr expression, its use and composition
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
EP2855500B1 (en) * 2012-05-24 2020-07-01 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
WO2014139885A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
JP2016518812A (en) 2013-03-14 2016-06-30 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Molecular targets useful in the treatment of fibrosis and inhibitors of said targets
EP2972322B1 (en) 2013-03-14 2019-03-06 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
WO2015003113A2 (en) 2013-07-03 2015-01-08 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
CN106103718B (en) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 Hexokinase (KHK) iRNA compositions and methods of use
WO2015171918A2 (en) * 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11965216B2 (en) 2015-04-07 2024-04-23 Polyskope Labs Detection of one or more pathogens
JP6885596B2 (en) * 2015-05-11 2021-06-16 マードック・ユニヴァーシティ Treatment of multiple sclerosis
AU2016294347B2 (en) * 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)
CN105349665B (en) * 2015-11-27 2018-06-19 上海锐赛生物技术有限公司 Kit of colorectal cancer risk of recurrence and application thereof after assessment oxaliplatin chemotherapeutic
AU2017205462A1 (en) 2016-01-05 2018-06-07 Ionis Pharmaceuticals, Inc. Methods for reducing LRRK2 expression
WO2017207656A1 (en) * 2016-05-31 2017-12-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system
WO2019010274A1 (en) 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
EP3664813A4 (en) 2017-08-10 2021-08-11 Washington University COMPOSITIONS AND METHODS OF TREATMENT WITH NICOTINAMIDE MONONUCLEOTIDE
CN108387621B (en) * 2018-01-10 2019-11-26 暨南大学 Cadmium ion aptamer and screen printing electrode electrochemica biological sensor
TWI833770B (en) 2018-06-27 2024-03-01 美商Ionis製藥公司 Compounds and methods for reducing lrrk2 expression
CN109402117B (en) * 2018-11-07 2022-03-01 上海中医药大学附属曙光医院 Adeno-associated virus for silencing expression of mouse intestinal RASGRP1 and preparation method and application thereof
WO2020101880A1 (en) * 2018-11-14 2020-05-22 Oklahoma Medical Research Foundation Compositions and methods of treating systemic lupus erythematosus
EP3894559A4 (en) * 2018-12-03 2023-04-05 Triplet Therapeutics, Inc. THERAPEUTIC METHODS FOR TRINUCLEOTIDE REPEAT EXPANSION DISEASES ASSOCIATED WITH MLH3 ACTIVITY
US20220062379A1 (en) * 2019-01-18 2022-03-03 The General Hospital Corporation Methods and compositions for modulating immune dysregulation
WO2021195574A1 (en) * 2020-03-27 2021-09-30 Alnylam Pharmaceuticals, Inc. Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4133077A1 (en) * 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2022066847A1 (en) * 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en) * 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP4298218A1 (en) 2021-02-26 2024-01-03 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
CN113430199A (en) * 2021-06-30 2021-09-24 武汉三鹰生物技术有限公司 Interfering sequence of HADHA mRNA and verification method thereof
US20230313198A1 (en) * 2021-12-17 2023-10-05 University Of Massachusetts Oligonucleotides for mlh3 modulation
WO2023154964A1 (en) * 2022-02-14 2023-08-17 Alloy Therapeutics, Inc. Methods and compositions for targeting efemp1
CN116064771A (en) * 2022-09-27 2023-05-05 中山大学 Function determination and application of a gene promoting cell ferroptosis
WO2025137323A1 (en) * 2023-12-22 2025-06-26 Empirico Inc. Treatment of cpn1 related diseases and disorders
CN118320133B (en) * 2024-06-14 2024-09-24 中国医学科学院基础医学研究所 Application of a recombinant adeno-associated virus in the treatment of heart failure
CN118853873A (en) * 2024-09-25 2024-10-29 温州医科大学附属第一医院 Application of WSB1 as a target in HPH disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924117B2 (en) * 2000-07-19 2005-08-02 Exelixis, Inc. Human RRP sequences and methods of use
WO2003012052A2 (en) * 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs

Also Published As

Publication number Publication date
AU2003224132A8 (en) 2004-11-19
WO2004094636A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
AU2003224132A1 (en) Effective sirna knock-down constructs
PL1807520T3 (en) Rna constructs
AU2013260680A1 (en) Precise breeding
AU2003272930A1 (en) Footwere
AU2003274573A1 (en) Deburrer
AU2003237303A1 (en) Aptamer constructs
IL169909A0 (en) Knock-down drums
GB0423659D0 (en) RNA constructs
AU2003233467A1 (en) Slender container
AU2003901418A0 (en) Sirna
AU2003273077A1 (en) Fan-combined heater
AU2003901457A0 (en) Alvan
AU2003100119A4 (en) Improved Shelving
AU2003906907A0 (en) Bioreactor
AU2003903871A0 (en) Bioreactor
AU2003904042A0 (en) Bioreactor
AU2003100942A4 (en) Energenz
AU2003100378A4 (en) Scootermansydney
AU2003100325A4 (en) Freez-A-Cube
AU2003100198A4 (en) Colourband Browbands
AU2003100006A4 (en) Adcaster
AU2003904390A0 (en) Arrow rest
AU2003904027A0 (en) Shellfish farming
AU2003900119A0 (en) Improved shelving
AU2003905988A0 (en) Improved Hammock

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 49, PAGE(S) 10021 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME GALAPAGOS GENOMICS N.V., APPLICATION NO. 2003224132, UNDER INID (71) CORRECT THE NAME TO READ GALAPAGOS GENOMICS N.V.; VAN DER SCHUEREN, JAN

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase